AorTech International PLC New Patent Issued (6329S)

TIDMAOR

RNS Number : 6329S

AorTech International PLC

26 June 2018

26 June 2018

AorTech International plc

("AorTech" or the "Company")

New Patent Issued

AorTech is pleased to announce that the US Patent Office has recently granted Patent Number 9,994,668 entitled "BIOSTABLE POLYURETHANES". The invention relates to polyurethanes and processes for their preparation. The polyurethanes are biostable, creep resistant, acid resistant and abrasion resistant which makes them useful in the manufacture of biomaterials and medical devices, articles or implants, in particular, long term implantable medical devices in the fields of cardiology, orthopaedics, plastic surgery and gastroenterology.

Bill Brown, Chairman of AorTech said: "We are delighted that this US Patent has been issued extending further AorTech's world class portfolio of biostable polymers for medical device use."

For further information contact:

   AorTech International plc                                            Tel: [phone] 

Bill Brown, Chairman

   Stockdale Securities Limited                                       Tel: [phone] 

Tom Griffiths/David Coaten

About AorTech:

AorTech has developed biostable, implantable polymers, including Elast-Eon(TM) and ECSil(TM) the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

Elast-Eon(TM) and ECSil(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.

In addition to the licensing of biostable polymers, AorTech is now developing medical devices utilising the key properties of its world class polymers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCLLFSLREIRFIT

(END) Dow Jones Newswires

June 26, 2018 07:49 ET (11:49 GMT)